In vitro diagnostics firm bioMérieux has announced the acquisition of LUMED, a software company that has developed a clinical decision support system to help hospitals optimise antimicrobial prescriptions and monitor healthcare-associated infections.
bioMérieux has acquired the entire share capital of Canadian innovative software company LUMED, increasing its stake from 16% to 100%. The two companies have been working closely together since 2017. The acquisition of 84% of the capital represents an investment close to €9 million.
Appropriate use of available data is essential for hospitals to provide safe and appropriate patient care, and control pharmacy costs. LUMED’s advanced software solutions help ensure that local antimicrobial prescription guidelines are followed and implemented. It gives healthcare professionals all the varied and relevant information they need to optimise their Antimicrobial Stewardship Programs (ASP) and their Infection Prevention and Control (IPC) programs, to provide better care for their patients, combat antimicrobial resistance (AMR) and improve infection control.
Diagnostic and other vital data generated all along the healthcare pathway, when analysed by intelligent software, are key in assisting the various health professionals in their decision-making process, to achieve optimal benefits for patients. LUMED’s solutions are a perfect complement to bioMérieux’s comprehensive suite of software solutions: BIOMÉRIEUX VISION SUITE.
“For bioMérieux, it is essential that we extend the scope of diagnostic testing beyond the laboratory itself. Today, many hospitals around the world are structuring themselves around the major issue of antimicrobial resistance and infection prevention. With LUMED, we provide solutions for antimicrobial stewardship teams to improve their daily workflow. The software contributes to optimising the process of care delivery, as well as costs and patient management,” declared Jennifer Zinn, Executive Vice President, Clinical Operations, bioMérieux.
